Skip to Content

Investor Relations

As of August 7, 2019, Option Care and BioScrip have merged to become one national team, solely dedicated to infusion care. Option Care Health, Inc. is the largest independent...
Read More

Corporate Profile

As of August 7, 2019, Option Care and BioScrip have merged to become one national team, solely dedicated to infusion care. Option Care Health, Inc. is the largest independent home and alternate site infusion services provider in the United States. With over 6,000 teammates including 2,900 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and employees.

Investor Overview

News Releases

Date Title and Summary
Toggle Summary Option Care Health to Announce Third Quarter 2020 Financial Results and Host Conference Call
BANNOCKBURN, Ill. , Oct. 13, 2020 (GLOBE NEWSWIRE) -- Option Care Health Inc. (“ Option Care Health”) (NASDAQ: OPCH), the nation’s largest independent national provider of home and alternate site infusion services, today announced that the company will release results for its third quarter ended
Toggle Summary Option Care Health to Participate in Upcoming Virtual Investor Conference
BANNOCKBURN, Ill. , Sept. 03, 2020 (GLOBE NEWSWIRE) -- Option Care Health Inc. (“ Option Care Health”) (NASDAQ: OPCH), the nation’s largest independent national provider of home and alternate site infusion services, will participate in the Lake Street 4 th Annual Best Ideas Growth Conference ,
Toggle Summary Option Care Health Selected as a Limited Distribution Provider of VILTEPSO™ (viltolarsen) Injection for Patients with Duchenne Muscular Dystrophy in Patients Amenable to Exon 53 Skipping Therapy
BANNOCKBURN, Ill. , Sept. 02, 2020 (GLOBE NEWSWIRE) -- Option Care Health, Inc.  (“ Option Care Health”) (NASDAQ: OPCH), the nation’s largest independent provider of home and alternate site infusion services, has been selected to participate in the limited distribution network of VILTEPSO™